Effects of various anti-inflammatory and anti-rheumatic agents on the synthesis, secretion, and activity of a cartilage proteoglycan-degrading enzyme and other macrophage enzymes

Ackerman, Neil R.; Jubb, Shizu N.; Marlowe, Steven L.

doi:10.1016/0006-2952(81)90236-7

Cited by 14 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lysosomal stabilisation by CQ and other anti-malarials Therapy and pharmacological properties of hydroxychloroquine and chloroquine could conceivably be a major site of action of these drugs in controlling degradation of connective tissues in arthritic conditions (Whitehouse and Cowley 1966). Several studies have shown that CQ inhibits degradation of proteoglycans in vitro and has direct effects on elastase and other enzymes released from macrophages (Whitehouse and Boström 1965;Cowey and Whitehouse 1966;Fulkerson et al 1979;Famaey and Fontaine 1980;Ackerman et al 1981;Tauber et al 1985;Bartholomew and Lowther 1987;Adeyemi et al 1990;Kamal and Bassiouni 1992;Schug and Kalbhen 1995;Lullmann-Rauch et al 1996). The central role of the destruction of cartilage (and bone) by pro-inflammatory cytokines (IL-1, TNFa) in arthritic conditions has been well recognised for several decades (Etherington et al 1981;Cox and Duff 1996).…”

Section: Cartilage Metabolism and Degradationmentioning

confidence: 96%

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

et al. 2015

View full text Add to dashboard Cite

HCQ and CQ have a good reputation for being effective and relatively safe treatments in SLE, mild-moderate RA and Sjøgren's syndrome. There is need for (a) more information on their mode of action in relation to the control of these diseases, (b) scope for developing formulations that have improved pharmacokinetic and therapeutic properties and safety, and (c) further exploring their use in drug combinations not only with other disease modifying agents but also with biologics.

show abstract

Section: Cartilage Metabolism and Degradationmentioning

confidence: 96%

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Cartilage degradation is mostly caused by pro-inflammatory cytokines, such as IL-1, IL-17 and TNFa, and their production can be repressed by HCQ treatment (Picot et al, 1991;Sperber et al, 1993;Van Den Borne et al, 1997;Jang et al, 2006;McInnes & Schett, 2007;da Silva et al, 2013). In vitro experiments have also established that CQ inhibits proteoglycan turnover (Fulkerson et al, 1979;Ackerman et al, 1981;Schug & Kalbhen, 1995;Rainsford et al, 2015), and early autoradiographic studies following tritium-labelled HCQ have revealed that this drug accumulates in the cartilage of mice (Cecchi & Porzio, 1964). These findings and its water-soluble properties led to the proposition that HCQ accumulates in the cartilage by binding acidic proteoglycans and protecting them from degradation by proteolytic enzymes (Rainsford et al, 2015).…”

Section: Clinical Impact Of Hcq On Radsmentioning

confidence: 99%

Hydroxychloroquine in rheumatic autoimmune disorders and beyond

2020

View full text Add to dashboard Cite

Initially used as antimalarial drugs, hydroxychloroquine ( HCQ ) and, to a lesser extent, chloroquine ( CQ ) are currently being used to treat several diseases. Due to its cost‐effectiveness, safety and efficacy, HCQ is especially used in rheumatic autoimmune disorders ( RAD s), such as systemic lupus erythematosus, primary Sjögren's syndrome and rheumatoid arthritis. Despite this widespread use in the clinic, HCQ molecular modes of action are still not completely understood. By influencing several cellular pathways through different mechanisms, CQ and HCQ inhibit multiple endolysosomal functions, including autophagy, as well as endosomal Toll‐like receptor activation and calcium signalling. These effects alter several aspects of the immune system with the synergistic consequence of reducing pro‐inflammatory cytokine production and release, one of the most marked symptoms of RAD s. Here, we review the current knowledge on the molecular modes of action of these drugs and the circumstances under which they trigger side effects. This is of particular importance as the therapeutic use of HCQ is expanding beyond the treatment of malaria and RAD s.

show abstract

“…При некоторых РЗ ГХ способен снижать уровень провоспалительных цитокинов: ФНОα, ИЛ1β, ИЛ6, ИЛ17, ИЛ18, ИЛ22. Накапливаясь в тканях сустава, ГХ может оказывать протективное влияние на хрящевую ткань, уменьшая разрушение протеогликанов и синтез провоспалительных цитокинов и протеолитических ферментов [37][38][39][40].…”

Section: гидроксихлорохин (гх)unclassified

Use of disease-modifying anti-rheumatic drugs in the therapy of osteoarthritis

Германович¹,

Алексеева²,

Лила³

2019

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Osteoarthritis (OA) is a heterogeneous disease with varying degrees of inflammatory responses, structural changes, functional insufficiency, and disease progression as a whole. Some OA phenotypes are characterized by a high local inflammatory response, persistent pain, persistent synovitis, and severe functional limitation. As a rule, the use of traditional nonsteroidal anti-inflammatory drugs in these patients and the injection of glucocorticoids into the joint show no substantial effect. Taking into account the important role of inflammation and the involvement of immune responses in the pathogenesis of OA, the existence of its erosive forms, the use of some disease-modifying anti-rheumatic drugs could be a rational solution of the problem in the therapy of this disease.The paper reviews data on the efficiency and safety of using methotrexate and hydroxychloroquine in OA.

show abstract

Effects of various anti-inflammatory and anti-rheumatic agents on the synthesis, secretion, and activity of a cartilage proteoglycan-degrading enzyme and other macrophage enzymes

Cited by 14 publications

References 37 publications

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Hydroxychloroquine in rheumatic autoimmune disorders and beyond

Use of disease-modifying anti-rheumatic drugs in the therapy of osteoarthritis

Contact Info

Product

Resources

About